ABOUT this BLOG and How to use it

WELCOME to Stu's Views & MS News, a product of MS Views and News, a Not-for-Profit 501(c3) organization. Founded in 2008. Providing Educational, Information and Resources to those affected by Multiple Sclerosis via live seminars and via the internet.

Key-Note: Our live MS educational seminars average approx 65 people per educational program and SINCE our first program in February 2010, we have hosted more than 90 educational programs in Florida. In 2013 we expanded to Georgia and in 2014 we have expanded further, into Alabama and North Carolina.

Register at our website to receive our globally transmitted Multiple Sclerosis e-newsletter, currently being received in more than (90) Countries.

Visit MS Views and News.org

Scroll to view All the resources found on the left side of this blog. Need to find information, use our 'search by topic' tool.

Be Empowered with MS News and Information

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Monday, January 7, 2013

Vaccinex, Inc. Announces Initiation of a Phase 1 Clinical Trial of VX15/2503 Antibody in Multiple Sclerosis Patients


ROCHESTER, N.Y.Jan. 7, 2013 /PRNewswire/ -- Vaccinex, Inc. announced today that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetics of therapeutic antibody candidate VX15/2503 in patients with multiple sclerosis.

VX15/2503 is a novel humanized monoclonal antibody targeting the multi-functional protein semaphorin 4D (SEMA4D), and represents the second clinical trial for this investigational drug.  Signaling cascades initiated by SEMA4D regulate activation and migration of inflammatory cells, inhibit remyelination, and disrupt endothelial tight junctions leading to breakdown of the blood-brain barrier.  

Each of these mechanisms is known to contribute to the severity and progression of neuroinflammatory/neurodegenerative diseases including multiple sclerosis.  Studies in multiple animal models have shown that anti-SEMA4D antibody can successfully ameliorate disease severity.

Dr. Maurice Zauderer , President and Chief Executive Officer of Vaccinex, said:  "It is particularly gratifying for Vaccinex to translate into the clinic the first therapeutic to target this important new class of regulatory molecules.  Research in our own and other laboratories has shown that the multiple activities of SEMA4D have a coordinated detrimental effect on progression of neurological diseases, several types of cancer, and some other inflammatory and/or degenerative conditions.  Vaccinex is currently completing a parallel trial of VX15/2503 antibody in patients with solid tumors and plans to continue to advance studies of the therapeutic benefit of this unique and novel agent."

About Vaccinex, Inc.
Founded in 1997 and located in Rochester, NY, Vaccinex, Inc. is a privately held clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies and vaccines to treat serious diseases with unmet needs, including cancer, multiple sclerosis, and other autoimmune diseases.   www.vaccinex.com.  

Press Contact Raymond E. Watkins , Chief Operating Officer, Vaccinex, Inc.
+1.585.271.2700

SOURCE Vaccinex, Inc.

PR Newswire (http://s.tt/1y3Dq)

..


If you would like, you can comment to our blog posts
 LIKE this Blog by clicking the LIKE button - top left
 REMAIN up to date with MS News and Education
Visit: www.msviewsandnews.org  to register
.

No comments: